Tumor Vaccines Frontier Applications in Tumor Microenvironment
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Cancer Vaccines and Immunotherapy".
Deadline for manuscript submissions: closed (30 November 2023) | Viewed by 2579
Special Issue Editors
Interests: tumor immune; tumor therapy
Interests: mechanism of autoimmune thyroid diseases, mainly including Graves' disease and hypothyroidism
Interests: tumor microenvironment; tumor vaccine; molecular mechanism; precision medicine; gene therapy
2. The Urology Institute, University Hospitals Cleveland Medical Center, Cleveland, OH 44106, USA
Interests: breast cancer; cell culture; in silico drug design; phytochemistry; androgen deprivation therapy; cancer biology; cell signaling; prostate cancer; immunoprecipitation; Western blot analysis
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
When a tumor vaccine enters the human body, it needs to go through a series of complex immune responses to finally achieve the purpose of treatment. However, this complex set of immune responses occurs in the tumor microenvironment. The tumor microenvironment is the internal environment responsible for the production and existence of tumor cells, including not only the tumor cells themselves, but also various cells such as fibroblasts, immune cells, inflammatory cells, glial cells and other cells around the tumor cells, as well as intercellular stroma, microvascular and biomolecules infiltrated in the nearby area. At present, due to our insufficient understanding of the tumor microenvironment, the development of tumor vaccines is very slow. Therefore, in-depth exploration of the tumor microenvironment is of great value for the development of new tumor vaccines.
We welcome the submission of original research and review articles to this Special Issue to gain insight into the molecular mechanisms of the tumor microenvironment in tumorigenesis and development, which will help guide the development of novel oncology vaccines and the clinical treatment of oncology patients. We will not accept data-analysis-only manuscripts, and cell or drug trials in vitro should be supplemented to meet our inclusion criteria. Potential topics include, but are not limited to, the following:
- Tumor microenvironment and oncology vaccines;
- Cancer immunology and cancer treatment;
- Innate and adaptive immune cells;
- Peptide vaccines and solid tumors;
- Genetically engineered vaccines and tumors;
- Antibody tumor vaccines and tumors.
Dr. Yutao Wang
Dr. Qiuming Yao
Dr. Yingkun Xu
Dr. Prem Prakash Kushwaha
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- tumor vaccines
- antibody tumor vaccines
- genetically engineered vaccines
- peptide vaccines
